CURE.DE vs. XGEN.DE
CURE.DE (VanEck Genomics and Healthcare Innovators UCITS ETF A) and XGEN.DE (Xtrackers MSCI Genomic Healthcare Innovation UCITS ETF 1C) are both Health & Biotech Equities funds - CURE.DE tracks the MVIS Global Future Healthcare ESG while XGEN.DE tracks the MSCI ACWI IMI Genomic Innovation Select ESG Screened 100. Both are passively managed. Over the past 3 years, CURE.DE returned -2.48%/yr vs 1.39%/yr for XGEN.DE. Their correlation of 0.84 suggests significant overlap in exposure. CURE.DE charges 0.35%/yr vs 0.30%/yr for XGEN.DE.
Performance
CURE.DE vs. XGEN.DE - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, CURE.DE achieves a -5.10% return, which is significantly lower than XGEN.DE's -1.40% return.
CURE.DE
- 1D
- 4.01%
- 1M
- 7.19%
- YTD
- -5.10%
- 6M
- -8.94%
- 1Y
- 5.80%
- 3Y*
- -2.48%
- 5Y*
- —
- 10Y*
- —
XGEN.DE
- 1D
- 3.92%
- 1M
- 6.45%
- YTD
- -1.40%
- 6M
- -3.78%
- 1Y
- 22.37%
- 3Y*
- 1.39%
- 5Y*
- —
- 10Y*
- —
CURE.DE vs. XGEN.DE - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
CURE.DE VanEck Genomics and Healthcare Innovators UCITS ETF A | -5.10% | 5.09% | 0.30% | -6.42% | -4.35% |
XGEN.DE Xtrackers MSCI Genomic Healthcare Innovation UCITS ETF 1C | -1.40% | 7.38% | 2.95% | -5.84% | -7.80% |
Correlation
The correlation between CURE.DE and XGEN.DE is 0.84, indicating a strong positive relationship between their price movements. Combining them offers limited diversification - they tend to fall together during downturns.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.84 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.83 |
Correlation (All Time) Calculated using the full available price history since Sep 8, 2022 | 0.84 |
The correlation between CURE.DE and XGEN.DE has been stable across timeframes, ranging from 0.83 to 0.84 - a consistent structural relationship.
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
CURE.DE vs. XGEN.DE — Risk / Return Rank
CURE.DE
XGEN.DE
CURE.DE vs. XGEN.DE - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for VanEck Genomics and Healthcare Innovators UCITS ETF A (CURE.DE) and Xtrackers MSCI Genomic Healthcare Innovation UCITS ETF 1C (XGEN.DE). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| CURE.DE | XGEN.DE | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.94 | ||
| Sortino ratioReturn per unit of downside risk | -1.29 | ||
| Omega ratioGain probability vs. loss probability | 1.06 | 1.21 | -0.15 |
| Calmar ratioReturn relative to maximum drawdown | 0.30 | 1.49 | -1.18 |
| Martin ratioReturn relative to average drawdown | 0.68 | 3.61 | -2.93 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| CURE.DE | XGEN.DE | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 0.29 | 1.23 | -0.94 |
Sharpe Ratio (All Time)Calculated using the full available price history | -0.14 | -0.11 | -0.03 |
Drawdowns
CURE.DE vs. XGEN.DE - Drawdown Comparison
The maximum CURE.DE drawdown since its inception was -34.80%, smaller than the maximum XGEN.DE drawdown of -37.58%. Use the drawdown chart below to compare losses from any high point for CURE.DE and XGEN.DE.
Loading charts...
Drawdown Indicators
| CURE.DE | XGEN.DE | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -34.80% | -37.58% | +2.78% |
Max Drawdown (1Y)Largest decline over 1 year | -19.07% | -14.99% | -4.08% |
Max Drawdown (3Y)Largest decline over 3 years | -29.32% | -28.21% | -1.11% |
Current DrawdownCurrent decline from peak | -15.66% | -14.86% | -0.80% |
Average DrawdownAverage peak-to-trough decline | -15.12% | -19.44% | +4.32% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 8.53% | 6.19% | +2.34% |
Volatility
CURE.DE vs. XGEN.DE - Volatility Comparison
The current volatility for VanEck Genomics and Healthcare Innovators UCITS ETF A (CURE.DE) is 5.73%, while Xtrackers MSCI Genomic Healthcare Innovation UCITS ETF 1C (XGEN.DE) has a volatility of 6.48%. This indicates that CURE.DE experiences smaller price fluctuations and is considered to be less risky than XGEN.DE based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| CURE.DE | XGEN.DE | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 5.73% | 6.48% | -0.75% |
Volatility (6M)Calculated over the trailing 6-month period | 15.20% | 13.73% | +1.47% |
Volatility (1Y)Calculated over the trailing 1-year period | 19.97% | 18.19% | +1.78% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 20.74% | 18.66% | +2.08% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 20.74% | 18.66% | +2.08% |
CURE.DE vs. XGEN.DE - Expense Ratio Comparison
CURE.DE has a 0.35% expense ratio, which is higher than XGEN.DE's 0.30% expense ratio.
Dividends
CURE.DE vs. XGEN.DE - Dividend Comparison
Neither CURE.DE nor XGEN.DE has paid dividends to shareholders.
Frequently Asked Questions
CURE.DE and XGEN.DE have a correlation of 0.84, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
On fees, XGEN.DE is cheaper at 0.30% per year. The better choice depends on whether you care most about return, fees, risk, or income.
XGEN.DE is cheaper with a 0.30% expense ratio, compared with 0.35% for CURE.DE.
CURE.DE tracks MVIS Global Future Healthcare ESG, while XGEN.DE tracks MSCI ACWI IMI Genomic Innovation Select ESG Screened 100. They also come from different issuers: VanEck and Xtrackers. Their fees differ too: 0.35% for CURE.DE and 0.30% for XGEN.DE.
Find the right allocation for CURE.DE and XGEN.DE
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer